NCT00831896已完成1 期
A Multicenter, Open-Label, Dose Escalation Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematologic Malignancies
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 27
- 试验地点
- 3
- 主要终点
- Safety profile (adverse events including dose limiting toxicities, clinical safety assessments such as human antihumanized antibody (HAHA) and neutr. HAHA), tolerability (maximum tolerated dose or maximum feasible dose), and pharmacokinetic profile.
研究概览
简要总结
This study is a multicenter, open-label, dose escalation, phase 1 study of TAK 701 in adult patients with advanced nonhematologic malignancies. This study will be the first to administer TAK 701 to humans. The primary purpose of this study is to determine the safety profile, tolerability, and pharmacokinetics profile of TAK-701.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged 18 years or older.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-
- •Diagnosis of a nonhematologic malignancy for which standard curative or lifeprolonging treatment does not exist or is no longer effective.
- •Radiographically or clinically evaluable tumor; however, measurable disease is not required for participation in this study (eg, patients with pleural effusion or ascites).
- •Female patients who:
- •Are postmenopausal for at least 1 year before the screening visit, or
- •Are surgically sterile, or
- •If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 3 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.
- •Male patients, even if surgically sterilized (ie, status postvasectomy), who:
- •Agree to practice effective barrier contraception during the entire study drug treatment period and through 3 months after the last dose of TAK-701, or
- •Agree to completely abstain from heterosexual intercourse.
- •Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
排除标准
- •Female patients who are lactating or have a positive serum pregnancy test during the screening period.
- •Major surgery within 14 days before the first dose of TAK-701 or any planned/anticipated surgery during the study period.
- •Positive test for Hepatitis B or C infection.
- •Active alcohol abuse
- •Active infection requiring systemic therapy, or other serious infection.
- •Antineoplastic therapy (including unconjugated therapeutic antibodies and toxin immunoconjugates) or any experimental therapy within 21 days before the first dose of TAK-
- •Radiotherapy within 21 days before the first dose of TAK-
- •Nitrosoureas or mitomycin-C within 6 weeks before the first dose of TAK-
- •Autologous stem cell transplant within 3 months before the first dose of TAK-701, or prior allogeneic stem cell transplant at any time.
- •Any prior exposure to anti-HGF therapy (eg, AMG-102, AV-299).
- •The patient has symptomatic brain metastasis.
- •Absolute neutrophil count < 1,500/mm3; platelet count < 100,000/mm
- •Calculated creatinine clearance < 50mL/minute
- •Any of the following clinical laboratory results during screening (ie, within 28 days before the first dose of TAK-701):
- •Bilirubin > 1.5 times the upper limit of the normal range (ULN).
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 times the ULN. AST and ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to the presence of metastatic disease to liver and/or to bone.
- •Known human immunodeficiency virus (HIV) positive.
- •Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- •Uncontrolled cardiovascular condition, including ongoing cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months.
- •Patients having QTc > 470 msec on a 12-lead ECG obtained within 28 days before first study drug administration.
- •Presence of serious or nonhealing wound, ulcer or bone fracture.
研究组 & 干预措施
1
Experimental
TAK-701
干预措施: TAK-701 (Biological)
结局指标
主要结局
Safety profile (adverse events including dose limiting toxicities, clinical safety assessments such as human antihumanized antibody (HAHA) and neutr. HAHA), tolerability (maximum tolerated dose or maximum feasible dose), and pharmacokinetic profile.
时间窗: Duration of study
次要结局
- Pharmacodynamic profile, cardiac repolarization effects, antitumor activity, and recommended Phase 2 dose of TAK-701(Duration of study)
- Investigator's assessment of disease response using Response Evaluation Criteria in Solid Tumors guidelines and relevant tumor markers in serum such as PSA, CA 125 and CA 19-9(Duration of study)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma MalignanciesAdvanced Solid Tumor and Lymphoma MalignanciesNCT02000934Calithera Biosciences, Inc143
招募中
1 期
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid TumorNCT06270706Pliant Therapeutics, Inc.124
已完成
1 期
A Study of CDX-585 in Patients With Advanced MalignanciesFallopian Tube CancerBladder Urothelial CarcinomaHepatic CancerPrimary Peritoneal CarcinomaHead and Neck CancerOther Solid TumorsCholangiocarcinomaColorectal CancerOvarian CancerPancreatic CancerGastric CancerNon-small Cell Lung CancerEsophageal CancerRenal Cell CarcinomaNCT05788484Celldex Therapeutics20
撤回
1 期
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.Non-small Cell Lung Cancer (NSCLC)Solid TumorsEndometrialLiposarcomaBreast CancerOvarian CancerNCT05905341Pfizer
Unknown
1 期
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaMultiple MyelomaLymphomaNCT04818372Keymed Biosciences Co.Ltd87